Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
作者信息
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
出版信息
Oncologist. 2021 Mar;26(3):e522. doi: 10.1002/onco.13691.
Abstract
摘要
相似文献
1
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌患者中阿贝西利相关不良事件的管理：MONARCH 2和MONARCH 3的安全性分析
Oncologist. 2021 Mar;26(3):e522. doi: 10.1002/onco.13691.
2
Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.在MONARCH 2和MONARCH 3研究中接受阿贝西利治疗的日本晚期乳腺癌患者的安全性：对治疗中出现的中性粒细胞减少、腹泻以及丙氨酸转氨酶和天冬氨酸转氨酶水平升高的评估。
Cancer Manag Res. 2022 Mar 19;14:1179-1194. doi: 10.2147/CMAR.S348591. eCollection 2022.
3
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.MONARCH 2 研究：阿贝西利联合氟维司群治疗 HR+/HER2-晚期乳腺癌患者的疗效，这些患者在接受内分泌治疗时发生了进展。
J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3.
4
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.MONARCH 3：阿贝西利作为晚期乳腺癌初始治疗。
J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.
5
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.阿贝西利：治疗乳腺癌的新型 CDK4/6 抑制剂。
Ann Pharmacother. 2019 Feb;53(2):178-185. doi: 10.1177/1060028018795146. Epub 2018 Aug 13.
6
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.激素受体阳性晚期乳腺癌的预后特征及阿贝西利疗效的特征分析
NPJ Breast Cancer. 2018 Dec 18;4:41. doi: 10.1038/s41523-018-0094-2. eCollection 2018.
7
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer.对于激素受体阳性（HR+）/人表皮受体2阴性（HER-2）的晚期或转移性乳腺癌患者，在先前内分泌治疗期间病情进展或复发后的一线及后续治疗中，引入第三种细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂并不会改变成本效益状况。
J Oncol Pharm Pract. 2020 Sep;26(6):1486-1491. doi: 10.1177/1078155220934531. Epub 2020 Jun 23.
8
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.用于治疗转移性乳腺癌的细胞周期蛋白依赖性激酶抑制剂的最新全面综述。
Curr Med Res Opin. 2017 Sep;33(9):1559-1569. doi: 10.1080/03007995.2017.1348344. Epub 2017 Jul 25.
9
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.细胞周期蛋白依赖性激酶4/6抑制剂在当前及未来癌症治疗时代的作用
J Oncol Pharm Pract. 2019 Jan;25(1):110-129. doi: 10.1177/1078155218770904. Epub 2018 May 4.
10
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer.MONARCH 1 研究：阿贝西利（一种 CDK4 和 CDK6 抑制剂）单药治疗难治性 HR/HER2 转移性乳腺癌的 II 期研究。
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22.
引用本文的文献
1
Abemaciclib-Associated Panniculitis With Fibrosis: Expanding the Dermatologic Spectrum of Cyclin-Dependent Kinase 4/6 Inhibitors.阿贝西利相关的伴有纤维化的脂膜炎：扩展细胞周期蛋白依赖性激酶4/6抑制剂的皮肤病学谱
Cureus. 2025 May 2;17(5):e83380. doi: 10.7759/cureus.83380. eCollection 2025 May.
2
Local Control of Advanced Breast Cancer-Debate in Multidisciplinary Tumor Board.晚期乳腺癌的局部控制——多学科肿瘤委员会中的争论
J Clin Med. 2025 Jan 15;14(2):510. doi: 10.3390/jcm14020510.
3
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer.推进治疗选择：HR+/HER2-转移性乳腺癌中的CDK4/6抑制剂转换
Breast. 2025 Feb;79:103875. doi: 10.1016/j.breast.2025.103875. Epub 2025 Jan 10.
4
Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors.功能筛选揭示了非典型畸胎样横纹肌样瘤中的基因依赖性和不同的细胞周期调控。
Genome Biol. 2024 Dec 2;25(1):301. doi: 10.1186/s13059-024-03438-w.
5
Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer.阿贝西利治疗子宫内膜癌的前景。
Curr Oncol. 2024 Sep 12;31(9):5374-5383. doi: 10.3390/curroncol31090397.
6
Challenges of Renal Function Assessment in Breast Cancer Patients Treated With Abemaciclib: A Case Report.阿贝西利治疗的乳腺癌患者肾功能评估的挑战：一例报告
Cureus. 2024 Aug 25;16(8):e67714. doi: 10.7759/cureus.67714. eCollection 2024 Aug.
7
Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.环细胞依赖性激酶 4/6 抑制剂所致精神不良反应谱：FDA 不良事件报告系统的药物警戒分析。
CNS Neurosci Ther. 2024 Jul;30(7):e14862. doi: 10.1111/cns.14862.
8
A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.阿贝西利治疗多线治疗转移性去势抵抗性前列腺癌患者的探索性研究：CYCLONE 1 研究结果。
Clin Cancer Res. 2024 Jun 3;30(11):2377-2383. doi: 10.1158/1078-0432.CCR-23-3436.
9
Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients.亚洲患者中帕博西尼相关中性粒细胞减少症发生率较高的临床和基因分析。
Oncologist. 2024 Apr 4;29(4):e455-e466. doi: 10.1093/oncolo/oyad304.
10
Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation.阿贝西利潜在毒性的临床管理及确保治疗连续性的方法。
Asian Pac J Cancer Prev. 2023 Jun 1;24(6):1955-1962. doi: 10.31557/APJCP.2023.24.6.1955.
Zotero 插件